Evidence map›Paper›PMID 23468623›Full record

ArticlePLoS pathogens2013

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Megan K Murphy, Ling Yue, Ruimin Pan, Saikat Boliar, Anurag Sethi, Jianhui Tian, Katja Pfafferot, Etienne Karita, Susan A Allen, Emmanuel Cormier and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Megan K MurphyImmunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, Georgia, United States of America.
Ling Yue
Ruimin Pan
Saikat Boliar
Anurag Sethi
Jianhui Tian
Katja Pfafferot
Etienne Karita
Susan A Allen
Emmanuel Cormier
Paul A Goepfert
Persephone Borrow
James E Robinson
S Gnanakaran
Eric Hunter
Xiang-Peng Kong
Cynthia A Derdeyn
Emory University · USLos Alamos National Laboratory · USNew York University · USUniversity of Oxford · GBInternational HIV/AIDS Alliance · GBTulane University · USUniversity of Alabama at Birmingham · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Viral Immunology CoreP01AI088610 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KRATCHMAROV, TCHAVDAR P. · 2010 to 2014
$15.3M
Variation in HIV-1 R5 Envs: Consequences for tropism, neutralization & vaccinesP01AI082274 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2013
$9.7M
Virologic Correlates of Heterosexual TransmissionR37AI051231 · NIAID · EMORY UNIVERSITY · PI HUNTER, ERIC · 2008 to 2017
$9.6M
Role of V1V2 in HIV transmission and pathogenesisR01AI058706 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DERDEYN, CYNTHIA ANN · 2004 to 2016
$6.7M
NIAID NIH HHS P01 AI082274NIAID NIH HHS P01-AI082274NIAID NIH HHS P01 AI088610NIAID NIH HHS P01-AI088610NIAID NIH HHS P30 AI050409NIAID NIH HHS P30-AI050409NIAID NIH HHS R01 AI058706NIAID NIH HHS R01-AI058706NIAID NIH HHS R01 AI064060NIAID NIH HHS R01-AI064060NIAID NIH HHS R37 AI051231NIAID NIH HHS R37-AI051231
6 · The paper itself

Abstract

Antibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subset of HIV-1 infected subjects during chronic infection. Exact mechanisms that expand the otherwise narrow neutralization capacity observed during early infection are, however, currently undefined. Here we characterized the earliest nAb responses in a subtype A HIV-1 infected Rwandan seroconverter who later developed moderate cross-clade nAb breadth, using (i) envelope (Env) glycoproteins from the transmitted/founder virus and twenty longitudinal nAb escape variants, (ii) longitudinal autologous plasma, and (iii) autologous monoclonal antibodies (mAbs). Initially, nAbs targeted a single region of gp120, which flanked the V3 domain and involved the alpha2 helix. A single amino acid change at one of three positions in this region conferred early escape. One immunoglobulin heavy chain and two light chains recovered from autologous B cells comprised two mAbs, 19.3H-L1 and 19.3H-L3, which neutralized the founder Env along with one or three of the early escape variants carrying these mutations, respectively. Neither mAb neutralized later nAb escape or heterologous Envs. Crystal structures of the antigen-binding fragments (Fabs) revealed flat epitope contact surfaces, where minimal light chain mutation in 19.3H-L3 allowed for additional antigenic interactions. Resistance to mAb neutralization arose in later Envs through alteration of two glycans spatially adjacent to the initial escape signatures. The cross-neutralizing nAbs that ultimately developed failed to target any of the defined V3-proximal changes generated during the first year of infection in this subject. Our data demonstrate that this subject's first recognized nAb epitope elicited strain-specific mAbs, which incrementally acquired autologous breadth, and directed later B cell responses to target distinct portions of Env. This immune re-focusing could have triggered the evolution of cross-clade antibodies and suggests that exposure to a specific sequence of immune escape variants might promote broad humoral responses during HIV-1 infection.

Indexed as

Amino Acid SequenceAntibodies, NeutralizingAntibodies, ViralCross ReactionsFemaleHIV-1HIV InfectionsHIV SeropositivityHumansImmune EvasionImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsMaleMolecular Sequence DataProtein Structure, TertiarySequence AlignmentAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Heavy ChainsImmunoglobulin Light Chains

Identifiers

PMID23468623
PMCPMC3585129
OpenAlexW2058416188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.